WEED, Inc. is actively pursuing scientific solutions to fulfill the growing demand for treatments, therapies, products and hopeful cures of human and animal diseases.
WEED, Inc. is developing scientifically valid and evidence-based cannabis strains for the production of disease-specific medicines.
WEED, Inc. is eighteen months into a five-year Cannabis Genomic Study. The goal of the study is to complete a Global Genomic Classification of the Cannabis plant genus.
WEED, Inc.’s wholly owned subsidiary Sangre BioSciences has evaluated, updated and validated new methods for DNA extraction. Next generation purification, along with sequencing, annotation, and tissue culture techniques will allow new high-value cannabis strains to be identified and developed.
WEED, Inc. plans to use the completed Global Genomic Classification to develop new cannabis strains that show the highest likelihood of being successful in the treatment of a variety of animal and human diseases.
WEED Inc.’s wholly owned subsidiary WEED Australia Ltd.’s nonprofit arm, The Cannabis Institute of Australia, is establishing the Australian Cannabis & Hemp Scientific Advisory Council to establish national protocols and procedures specific to Australia’s emerging medical cannabis and scientific research communities.
Be the first to receive the latest Industry and WEED INC. News & Updates.